Gary L. Johanning
Gary L. Johanning has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Anh Nguyen
College of Graduate Studies, California Northstate University, Elk Grove, CA 95757, USA
1 shared publication - Ashley R. Chappell
Department of Epidemiology, The University of Alabama at Birmingham, Birmingham, AL 35294, USA
1 shared publication - Chandrika J. Piyathilake
Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, AL, USA
1 shared publication - Pauline E. Jolly
Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, AL, United States
1 shared publication - Suguna Badiga
Department of Nutrition Sciences, The University of Alabama at Birmingham, Birmingham, AL 35294, USA
1 shared publication - Yihui Shi
California Pacific Medical Center Research Institute, Sutter Bay Hospitals, San Francisco, USA
1 shared publication
Latest Publications
- Open Access
Emerging Novel Combined CAR-T Cell Therapies
Chimeric antigen receptors (CAR) T cells are T cells engineered to express membrane receptors with high specificity to recognize specific target antigens presented by cancer cells and are co-stimulated with intracellular signals to increase the T cell response. CAR-T cell therapy is emerging as a novel therapeutic approach to improve T cell specificity that will lead to advances in precision medicine. CAR-T cells have had impressive outcomes in hematological malignancies. However, there continue to be significant limitations of these therapeutic responses in targeting solid malignancies such as heterogeneous antigens in solid tumors, tumor immunosuppressive microenvironment, risk of on-target/off-tumor, infiltrating CAR-T cells, immunosuppressive checkpoint molecules, and cytokines. This review paper summarizes recent approaches and innovations through combination therapies of CAR-T cells and other immunotherapy or small molecule drugs to counter the above disadvantages to potentiate the activity of CAR-T cells.
Open AccessEmerging Novel Combined CAR-T Cell Therapies
Chimeric antigen receptors (CAR) T cells are T cells engineered to express membrane receptors with high specificity to recognize specific target antigens presented by cancer cells and are co-stimulated with intracellular signals to increase the T cell response. CAR-T cell therapy is emerging as a novel therapeutic approach to improve T cell specificity that will lead to advances in precision medicine. CAR-T cells have had impressive outcomes in hematological malignancies. However, there continue to be significant limitations of these therapeutic responses in targeting solid malignancies such as heterogeneous antigens in solid tumors, tumor immunosuppressive microenvironment, risk of on-target/off-tumor, infiltrating CAR-T cells, immunosuppressive checkpoint molecules, and cytokines. This review paper summarizes recent approaches and innovations through combination therapies of CAR-T cells and other immunotherapy or small molecule drugs to counter the above disadvantages to potentiate the activity of CAR-T cells.
- Open Access
- 1 August 2021
- Published by Elsevier in Data in Brief
- Vol. 37, 107238
The dataset for the assessment of the inflammatory potential of the overall diet consumed by women of childbearing age
- 1 August 2021
- Published by Elsevier in Data in Brief
- Vol. 37, 107238
Open AccessThe dataset for the assessment of the inflammatory potential of the overall diet consumed by women of childbearing age